Mask Ventilation Before and After Neuromuscular Blockade

NCT ID: NCT02237443

Last Updated: 2015-04-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

210 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-31

Study Completion Date

2015-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Anesthesia providers are taught to "test" that they can properly ventilate a patient's lungs before administering a neuromuscular blocking drug (NMBD), rendering the patient apneic. This is a traditional teaching, not based on empirical evidence. The investigators primary hypothesis is that ventilation after the administration of NMBDs is non-inferior with that before their administration with respect to the composite safety endpoint of inadequate (MVi) and dead-space only (Vds) ventilation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The following will be carried out per routine standard of care:

The patient will be met in the pre-operative area by the attending anesthesiologist who interviews and examines the patient. A full explanation of the general anesthetic including risks and benefit will be given. Patients will be premedicated with 1-2 mg of midazolam at the discretion of the attending anesthesiologist. Once in the OR, standard American Society of Anesthesiology (ASA) monitors are established. At a minimum, this includes non-invasive monitoring of blood pressure by automated cuff, oxygen saturation via pulse oximetry, heart rate and rhythm by 3-lead continuous electrocardiographic tracing, core body temperature, expired carbon dioxide concentration, and depth of neuromuscular blockade when paralytic medications are used. Additional monitoring may be applied as deemed appropriate by the attending anesthesiologist on a case-by-case basis. At this time, the patient is given fentanyl 1-2 mcg/kg. After a period of breathing 100% oxygen by facemask (typically for 3 minutes or until the anesthesia monitor shows the exhaled concentration of oxygen to be \>80%) and when the primary anesthesia team judges denitrogenation to be sufficient, anesthesia will be induced intravenously with propofol 2-3 mg/kg. Once the patient is unresponsive to a jaw thrust, the patient is ventilated via a facemask. If the anesthesia provider feels that ability to move air in and out of the patients lungs is difficult, the may reposition the mask on the patient's face, reposition the head, neck, or shoulders of the patient, or place a plastic oropharyngeal airway to maintain the mouth in an open position and to help keep the base of the tongue from obstructing the upper airway. A drug that causes muscle paralysis is given, which takes 1-5 minutes to work depending on the drug administered; during this period the patient continues to be ventilated by facemask. However, there is not standard for the timing of administration of the paralytic drugs as some anesthesia providers administer them near simultaneous to the administration of the other drugs used to induce anesthesia. Often, during this time, an inhaled anesthetic agent is started to avoid any gaps in the effect of the intravenous medications. Once the muscle relaxant works, a breathing tube is placed in the patient's windpipe, and ventilation occurs via the tube connected to a breathing machine.

The study deviates from the standard anesthesia care described above in the following ways:

Before the patient arrives in the operating room, a small plastic device called a pneumotachograph will be placed in-line between the facemask and the breathing circuit of the anesthesia machine. This allows measurements of airway pressure and volumes to be recorded in an accurate manner and later sent electronically to a computer for analysis. The in-line portion of the device is no larger than a typical circuit connector already used and does not hinder the performance of the anesthesia provider in any way. After routine intravenous induction, once the patient is unresponsive to a jaw thrust patients will be ventilated by facemask for 60 seconds. Breaths will be delivered using the breathing bag of the anesthesia circuit as would otherwise be performed. The airway managers will be asked to follow a treatment algorithm to resolve any difficulty encountered in providing mask ventilation. This algorithm represents common practice. After the initial 60 seconds, the medication to induce muscle paralysis will be given. A nerve stimulator placed on the patients wrist will then be turned on and will indicate when the medication has taken full effect and the patient is paralyzed. During this period of time, approximately 60-90 seconds, with the patients unconscious and apneic, their breathing will be supported as would otherwise be done. Post-paralysis, data collection will again begin and the anesthesia provider will start again breathing for the patient via a facemask as described in figure 2 for another 60 seconds. The operator will be blinded to the display on the ventilator machine, which provides information about the amount of air going in and out of the patients lungs, but will be able to monitor the patient's pertinent vital signs on the anesthesia machine. At all times, one member of the primary anesthesia team will have full access to all monitoring as would normally take place. After this time, the tracheal tube will be placed for the surgery.

Appropriate sizing of the adult facemask and oropharyngeal airway will be determined by the primary anesthesia team. All breaths will be delivered by hand ventilation using the breathing bag of the anesthesia machine. The returned tidal volume will be recorded for each minute of the study period from the pneumotachograph placed inline with the anesthesia circuit at the level of the mask/elbow connector interface as described above. The total time from induction to placement of a breathing tube will be 4-5 minutes and represents an additional minute of "study" time to the standard care. This timing was chosen as the investigators feel that it will provide sufficient information about ventilation volumes without unduly prolonging the anesthetic.

The study coordinator will remain in the room for the actual intubation to record its ease or difficulty per the report of the primary anesthesia provider. The act of placing the breathing tube is not part of the study protocol, however.

Data points to be collected:

Data regarding tidal volume, minute ventilation, airway pressures, and end-tidal carbon dioxide will be recorded directly by the in-line pneumotachograph and then loaded into an excel spreadsheet. No manual data collection will be necessary.

Data and Safety Monitoring Plan

The study may be terminated by the primary anesthesia team if the one or more of the following criteria are met:

1. Inadequate ventilation by clinical criteria (inadequate chest rise, no fogging in the mask, no positive tracing of end-tidal carbon dioxide and/or lack of measurable returned tidal volumes on).
2. Low oxygen saturation (\< 90%).
3. If for any reason, the primary anesthesia team feel that in their clinical judgment, immediate tracheal intubation is warranted.

All unanticipated problems and adverse event will be recorded in the study sheet by a study coordinator. At the earliest time, each unanticipated problem and adverse event will be examined by at least 2 study investigators. In the event of an unanticipated problem of adverse effect (eg inadequate mask ventilation), back-up will be provided by the primary anesthesia team caring for the patient and may include placing a laryngeal mask airway or a surgical airway. These are the same provisions that would be made for any non-study case as mask ventilation by using one or two hands represents standard practice.

Statistical Considerations:

The investigators are aiming to show that administration of a neuromuscular blocking agent is "safe" with respect to mask ventilation. In other words, that the average exhaled tidal volume per breath over one minute after the administration of a NMBD will be non-inferior to that measured before their administration. At the time of the planning of this study, no studies had reported a mean±SD for tidal volumes before and after NMBDs. However, based upon a prior comparative trial of two different mask-hold techniques, the standard deviation (SD) of the average exhaled tidal volume after induction of anesthesia, using the anesthesia ventilator and a two-hand jaw-thrust mask hold technique was 130 mL. With the equivalence limit, d, set as 50 mL per breath, with a significance level (α) of 2.5% and a power (1-β) of 95%, a total sample size of 208 patients per group (before and after NMBD for a total sample of 416 study periods) were required. In other words, if there is truly no difference between the mask ventilation before and after NMBD, then 208 patients, each as their own control, are required to be 95% sure that the limits of a 2-sided 95% confidence interval will exclude a difference in means of \>50 mL.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Post-induction

Anesthesia is induced with propofol and mask ventilation is commenced after patient is unresponsive to a jaw thrust prior to administration of rocuronium, vecuronium bromide, or succinylcholine

Group Type OTHER

Rocuronium

Intervention Type DRUG

Administration of a NMBD

Vecuronium Bromide

Intervention Type DRUG

Administration of a NMBD

Succinylcholine

Intervention Type DRUG

Administration of a NMBD

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rocuronium

Administration of a NMBD

Intervention Type DRUG

Vecuronium Bromide

Administration of a NMBD

Intervention Type DRUG

Succinylcholine

Administration of a NMBD

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vecuronium Sux

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who are 18 years or greater
* Present for elective surgery and
* Require placement of a breathing tube for their surgery

Exclusion Criteria

* Patients will not be eligible if they are pregnant
* Are a minor
* Are a prisoner
* Have impaired decision-making capacity
* Have symptomatic untreated reflux
* Prior esophagectomy or hiatal hernia
* Vomiting within 24 hours of surgery
* Known oral or facial pathology making a proper mask fit unlikely
* Any condition for which the primary anesthesia team deems a rapid-sequence intubation to be appropriate
* Prior allergy or contraindication to receiving rocuronium, vecuronium, or succinylcholine.
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Washington

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Aaron Joffe

Assistant Professor, Anesthesiology & Pain Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Aaron M Joffe, DO

Role: PRINCIPAL_INVESTIGATOR

University of Washington Department of Anesthesiology and Pain Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Harborview Medical Center

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Joffe AM, Ramaiah R, Donahue E, Galgon RE, Thilen SR, Spiekerman CF, Bhananker SM. Ventilation by mask before and after the administration of neuromuscular blockade: a pragmatic non-inferiority trial. BMC Anesthesiol. 2015 Oct 6;15:134. doi: 10.1186/s12871-015-0111-z.

Reference Type DERIVED
PMID: 26444853 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

40262-D

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Selenium on Succinylcholine-Induced POM
NCT03476044 COMPLETED PHASE2/PHASE3